| Active substance | efgartigimod alfa |
| Holder | argenx |
| Status | Running |
| Indication | Acetylcholine receptor antibody negative patients with gMG who participated in and exited study ARGX-113-2002 OR who were treated via early access |
| Public documents | |
|
Information for the patient - amendment 1 |
|
|
Informed consent - amendment 1 |
|
| Last update | 07/07/2026 |